| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 08/08/2002 | US20020107276 Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist |
| 08/08/2002 | US20020107273 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 08/08/2002 | US20020107255 Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). |
| 08/08/2002 | US20020107254 P-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl) -piperazin-1-yl)-propyl)-N-pyridin-2-yl-benzamide, |
| 08/08/2002 | US20020107249 Administering a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine of at least about 5000, such as reboxetine; treating and prophylaxis of various psychological and neurological disorders |
| 08/08/2002 | US20020107178 Methods and preparations for curing clinically ill patients |
| 08/08/2002 | US20020106732 Smad6 and uses thereof |
| 08/08/2002 | US20020106726 Peptide for use in the treatment of inflammation defects |
| 08/08/2002 | US20020106655 Nucleotide sequences coding preferential protein for use in the treatment, diagnosis and prevention of immunological, nervous system and tumor disorders |
| 08/08/2002 | US20020106650 Nucleotide sequence coding preferential polypeptide; for use in the treatment, prevention and diagnosis of kidney, liver, reproductive and cardiovascular disorders |
| 08/08/2002 | US20020106630 Method of identifying HIBEF51 receptor inhibitors |
| 08/08/2002 | US20020106359 Method and composition for treating prostate cancer |
| 08/08/2002 | DE10104369A1 Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz Using 2-amino- (4-hydroxy-2-methanesulfonamidophenyl) ethanol for treating urinary incontinence |
| 08/08/2002 | CA2438594A1 Diazocine derivatives and their use as tryptase inhibitors |
| 08/08/2002 | CA2436748A1 Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing |
| 08/08/2002 | CA2436551A1 Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
| 08/08/2002 | CA2436544A1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 08/08/2002 | CA2436535A1 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes |
| 08/08/2002 | CA2436418A1 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 08/08/2002 | CA2436209A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates |
| 08/08/2002 | CA2434565A1 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence |
| 08/08/2002 | CA2432997A1 Antagonists of mcp-1 function and methods of use thereof |
| 08/08/2002 | CA2432642A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 08/08/2002 | CA2432369A1 Cyclic derivatives as modulators of chemokine receptor activity |
| 08/08/2002 | CA2431559A1 Process for making substituted 8-arylquinolinium benzenesulfonate |
| 08/08/2002 | CA2429969A1 Substituted indolines as 5-ht receptor ligands |
| 08/08/2002 | CA2427143A1 Compositions and methods for improving kidney function |
| 08/07/2002 | EP1229034A1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes |
| 08/07/2002 | EP1228222A2 Human transferase molecules |
| 08/07/2002 | EP1228092A1 24 human secreted proteins |
| 08/07/2002 | EP1228089A2 Salt form of a conjugate useful in the treatment of prostate cancer |
| 08/07/2002 | EP1228084A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 08/07/2002 | EP1228080A2 Compositions and methods for double-targeting virus infections and targeting cancer cells |
| 08/07/2002 | EP1228072A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 08/07/2002 | EP1228070A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 08/07/2002 | EP1228067A1 5-membered n-heterocyclic compounds with hypogylcemic and hypolipidemic activity |
| 08/07/2002 | EP1228061A1 Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| 08/07/2002 | EP1228055A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 08/07/2002 | EP1228047A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 08/07/2002 | EP1228046A1 Phthalazinone derivatives as pde 4 inhibitors |
| 08/07/2002 | EP1227813A1 Reverse-turn mimetics and methods relating thereto |
| 08/07/2002 | EP1227806A1 Pharmaceutical formulation containing tolterodine and its use |
| 08/07/2002 | EP1227791A2 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 08/07/2002 | EP0906276B1 Novel vitamin d analogues |
| 08/07/2002 | EP0809517B1 Anti-transforming growth factor-beta gene therapy |
| 08/07/2002 | CN1362954A Sulfamato hydroxamic acid metalloprotease inhibitor |
| 08/07/2002 | CN1362953A Pyrazole compositions useful as inhibitors of ERK |
| 08/07/2002 | CN1362237A Nano Sanjin medicine and its preparation |
| 08/07/2002 | CN1362163A Nano Jieshitong medicine for eliminating stone and its preparation |
| 08/07/2002 | CN1362162A Nano Niaoganning medicine and its preparation |
| 08/07/2002 | CN1362153A Nano mixed Shilingtong medicine and its preparation |
| 08/07/2002 | CN1362149A Nano Qianlietong medicine for treating prostatosis and its preparation |
| 08/07/2002 | CN1362144A Nano urination decreasing medicine and its preparation |
| 08/07/2002 | CN1362142A Nano Niaosaitong medicine for dredging urethra and its preparation |
| 08/07/2002 | CN1362140A Nano stone excreting medicine and its preparation |
| 08/07/2002 | CN1362088A Nano nephritis treating medicine and its preparation |
| 08/07/2002 | CN1362078A Nano indian chrysanthemum flower medicine and its preparation |
| 08/06/2002 | US6429313 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 08/06/2002 | US6429229 Keto acid salts and amine derivatives, and their use for preparing medicines |
| 08/06/2002 | US6429223 Modified forms of pharmacologically active agents and uses therefor |
| 08/06/2002 | US6428785 Local administration of therapeutically effective concentration of collagenase for therapy of prostate cancer in mammal |
| 08/01/2002 | WO2002059308A2 Method of diagnosing and treating cartilage disorders |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059295A1 Novel serine protease mp493 |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059156A2 Therapeutic compounds structurally-linked to bacterial polypeptides |
| 08/01/2002 | WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059109A2 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases |
| 08/01/2002 | WO2002059083A2 Novel compounds |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058627A2 A cystic fibrosis transmembrane-conductance regulator (cftr)-membrane translocation sequence fusion protein (cftr-mts) as a therapeutic agent |
| 08/01/2002 | WO2002043712A3 Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002026733A3 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 08/01/2002 | WO2002022572A3 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002005794A3 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 08/01/2002 | WO2002004509A3 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 08/01/2002 | WO2001096565A3 Binding agents: chimeric ligand/receptor proteins |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | WO2001012206A3 Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
| 08/01/2002 | US20020103376 Dithiepino[6,5-b]pyridines, and related compositions and methods |
| 08/01/2002 | US20020103248 Indole derivatives which are agonists of the progesterone receptor and useful for treatment of carcinoma and adenocarcinomas of uterine leiomyomata, endometriosis or polycystic ovary syndorme in a mammal |
| 08/01/2002 | US20020103239 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity |
| 08/01/2002 | US20020103229 Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| 08/01/2002 | US20020103227 Nitric oxide synthase inhibitors such as 6(4'-(4-phenethyl-piperazin-1-ylmethyl)-biphenyl-4-yl)-pyridin-2-ylamine for treatment and prevention of central nervous system disorders |
| 08/01/2002 | US20020103221 Such as 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo -(4,3-c)pyridin-5-yl)-1-(R)-benzyloxymethyl- 2-oxo-ethyl)-isobutyramide or prodrug thereof; for improving functional health of elderly/isolated |
| 08/01/2002 | US20020103198 Acylamino cyclopropane derivatives |
| 08/01/2002 | US20020103182 Improving elasticity or reducing wrinkles of a skin, for example; advanced glycosylation endproducts" or AGEs |
| 08/01/2002 | US20020103172 Vitamin d3 derivatives |
| 08/01/2002 | US20020103141 DNA topoisomerase I and cyclooxygenase-2 (COX-2) inhibiting agents |
| 08/01/2002 | US20020103123 Administering coumpounds such as aromatic alkyl diamine derivatives as Y5 receptor agonist or antagonist to increase or decrease food consumption |
| 08/01/2002 | US20020103112 Wound healing and treatment of fibrosis |
| 08/01/2002 | US20020102707 Nucleotide sequences coding polypeptide for use in the treatment of sexual disorders |
| 08/01/2002 | US20020102691 Enzymatic polypeptide for use in treatment and prevention of, heart liver and inflammatory disorders |